Search Result

Results for "

A431

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) ADC Cytotoxin (1) Akt (6) Antibiotic (2) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (16) Autophagy (10) Bacterial (8) Btk (1) c-Kit (3) c-Met/HGFR (8) Calcium Channel (1) Drug Derivative (3) EGFR (44) ERK (2) Estrogen Receptor/ERR (1) FAK (1) FLT3 (3) Fungal (1) Glutathione Peroxidase (1) Histone Demethylase (1) MMP (1) Necroptosis (1) NOD-like Receptor (NLR) (1) p38 MAPK (6) PDGFR (1) PGE synthase (1) Photosensitizer (1) Piezo Channel (1) PKA (1) PKC (1) Potassium Channel (1) Proton Pump (5) Reference Standards (1) STING (1) TAM Receptor (3) TMV (1) VEGFR (3) Wnt (1)
By Research Areas:	Cancer (65) Cardiovascular Disease (2) Infection (4) Inflammation/Immunology (8) Neurological Disease (1)

By Targets:

5-HT Receptor (1)

ADC Cytotoxin (1)

Akt (6)

Antibiotic (2)

Antibody-Drug Conjugates (ADCs) (1)

Apoptosis (16)

Autophagy (10)

Bacterial (8)

Btk (1)

c-Kit (3)

c-Met/HGFR (8)

Calcium Channel (1)

Drug Derivative (3)

EGFR (44)

ERK (2)

Estrogen Receptor/ERR (1)

FAK (1)

FLT3 (3)

Fungal (1)

Glutathione Peroxidase (1)

Histone Demethylase (1)

MMP (1)

Necroptosis (1)

NOD-like Receptor (NLR) (1)

p38 MAPK (6)

PDGFR (1)

PGE synthase (1)

Photosensitizer (1)

Piezo Channel (1)

PKA (1)

PKC (1)

Potassium Channel (1)

Proton Pump (5)

Reference Standards (1)

STING (1)

TAM Receptor (3)

TMV (1)

VEGFR (3)

Wnt (1)

By Research Areas:

Cancer (65)

Cardiovascular Disease (2)

Infection (4)

Inflammation/Immunology (8)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153697

FAK-IN-10	FAK	Cancer
FAK-IN-10 is an inhibitor of FAK with an IC₅₀ of 76.3 μM. FAK-IN-10 exhibits antitumor activity against MCF-7 and A431 cell lines with IC₅₀s of 4.23 and 0.78 μM,respectively .

HY-115963

Anticancer agent 38	Drug Derivative	Cancer
Anticancer agent 38 (compound 19), a sulfonylurea derivative, is a potent anticancer agent. Anticancer agent 38 inhibits A431 cell growth with an IC₅₀ of 5.2 µg/mL .

HY-157503

Photosensitizer-3	Photosensitizer	Cancer
Photosensitizer-3 is a photosensitizer that exhibits powerful selective killing effects on transfected HEK cells and affibody-targeted A431 cancer cells when exposed to near-infrared light excitation .

HY-162891

EGFR-IN-123	EGFR	Cancer
EGFR-IN-123 (compound D06) is a potent EGFR inhibitor. EGFR-IN-123 inhibits PC-9G, A549, A431 and HCT116 cells with IC₅₀s of 0.74, 1.36, 1.20 and 2.53 μM, respectively .

HY-142517

EGFR-IN-25	EGFR	Cancer
EGFR-IN-25 is a potent EGFR inhibitor with IC₅₀s of 9 nM and 60 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and A431 cells (WT), respectively .

HY-144872

RJ-34	Drug Derivative	Cancer
RJ-34, an aristolactam analogue, exhibits potent antitumor activities against a broad array of cancer cell lines with GI₅₀ values in the subnanomolar range (GI₅₀ <0.1 nM for A431, MES-SA, MES-SA/DX5, HCT-15, and HCT-15/CLO2 cells) .

HY-N14523

Gilvusmycin	Antibiotic Bacterial	Infection
Gilvusmycin is an antibiotic with strong anti-tumor activity. Gilvusmycin can inhibit P388, K562, A431 and MKN28 cells with IC₅₀s (ng/mL) of 0.08, 0.86, 0.72 and 0.75, respectively .

HY-171443

Lyso-Monosialoganglioside GM3 Lyso-GM3	EGFR Drug Derivative	Cancer
Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analogue of Ganglioside GM3 (HY-114456) with antitumor activities. Lyso-Monosialoganglioside inhibits EGF-induced increases in EGFR kinase activity in A431 epithelial cancer cells .

HY-115960

Anticancer agent 35	Others	Cancer
Anticancer agent 35 (compound 10), a sulfonylurea derivative, is a potent anticancer agent. Anticancer agent 35 inhibits A549, A431, PACA2 cell growth with IC₅₀s of 18.1 µg/mL, 4.0 µg/mL, 18.9 µg/mL, respectively .

HY-160682

EGFR/HER2-IN-12	EGFR	Others
EGFR/HER2-IN-12 (compound 14b) is a dual inhibitor of EGFR and HER2 with 81% and 51% inhibition at 10 μM. The toxicity of EGFR/HER2-IN-12 to cancer cells A431 and MDA-MB-361 was not significant .

HY-118184

AF3485	PGE synthase	Cancer
AF3485 is a human mPGES-1 inhibitor that exhibits antitumor activity in vitro and in vivo. AF3485 inhibits tumor-associated angiogenesis by reducing PGE2 production, inhibiting EGFR signaling, and decreasing VEGF and FGF-2 expression. AF3485 reduced tumor growth in mice bearing human A431 xenograft tumors by subchronic administration.

HY-N14056

Chrolactomycin	Bacterial	Infection Cancer
Chrolactomycin is found in the strain of Streptomyces sp. 569N-3. The IC₅₀ of Chrolactomycin for ACHN, A431, McF-7 and T24 cells are 1.2 μM, 1.6 μM, 0.69 μM and 0.45 μM, respectively. Chrolactomycin has only anti-Gram-positive bacteria activity with the MIC of 5.2-10.4 μg/mL .

HY-156741

EGFR-IN-87	EGFR	Cancer
EGFR-IN-87 (Compound Example 2) is a EGFR tyrosine kinase inhibitor. EGFR-IN-87 has IC₅₀ value of 3.1 nM, 1.3 nM and 7.1 nM for EGFR_d746-750, EGFR_L858R/T790 and EGFR_WT in A431 cells, respectively. EGFR-IN-87 can be used for cancer diseases research .

HY-156741A

EGFR-IN-87 hydrochloride	EGFR	Cancer
EGFR-IN-87 (Compound Example 2) hydrochloride is a EGFR tyrosine kinase inhibitor. EGFR-IN-87 hydrochloride has IC₅₀ value of 3.1 nM, 1.3 nM and 7.1 nM for EGFR_d746-750, EGFR_L858R/T790 and EGFR_WT in A431 cells, respectively. EGFR-IN-87 hydrochloride can be used for cancer diseases research .

HY-N12606

Neodidymelliosides A	Fungal	Infection
Neodidymelliosides A (compound 1)It is a secondary metabolite of fungi and has a significant inhibitory effect on Staphylococcus aureus and Candida albicans biofilms. Neodidymelliosides AIt also has anti-cancer activity and can inhibit KB3.1 (cervix),PC-3 (prostate),MCF-7(breast),SKOV-3 (ovary),A431 (skin )and A549 (lung )Cell viability of cell lines .

HY-132842

Sunvozertinib 1 Publications Verification DZD9008	EGFR Btk	Cancer
Sunvozertinib (DZD9008) is a potent ErbBs (EGFR, Her2, especially mutant forms) and BTK inhibitor. Sunvozertinib shows IC₅₀s of 20.4, 20.4, 1.1, 7.5, and 80.4 nM for EGFR exon 20 NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutations, and Her2 Exon20 YVMA, and EGFR WT A431, respectively (patent WO2019149164A1, example 52) .

HY-164056

EGFR T790M/L858R-IN-8	EGFR	Cancer
EGFR T790M/L858R-IN-8 (compound 9) is a potent inhibitor of EGFR, targeting mutant EGFR ^T790M/L858R with IC₅₀ of 56.8 μM. The anti-proliferative effect of EGFR T790M/L858R-IN-8 on cancer cell lines A549, A431, and NHI-H1975 is not significant .

HY-156912

Tyrosine kinase-IN-7	EGFR	Cancer
Tyrosine kinase-IN-7 (compound 13h) is an inhibitor of the tyrosine kinase EGFR. The IC₅₀s for inhibiting EGFR(WT) and EGFR(T790M) are 0.630 μM and 0.956 μM respectively. Tyrosine kinase-IN-7 has antitumor activity against four cancer cell lines (HepG2, HCT-116, MCF-7, and A431) with IC₅₀s of 13.02 μM, 10.14 μM, 12.68 μM, and 47.05 μM, respectively .

HY-121255

(-)-Cryptopleurine (R)-Cryptopleurine; NSC 19912	TMV	Cancer
(–)-Cryptopleurine is an alkaloid that has been found in Lauraceae and has diverse biological activities. It inhibits the growth of human A375 melanoma, A431 epidermoid carcinoma, A549 lung, MES-SA uterine sarcoma, and MCF-7 breast cancer cells (IC₅₀=3 nM for all).2 (–)-Cryptopleurine inhibits hypoxia-induced gene expression in a hypoxia response element (HRE) reporter assay (IC₅₀=8.7 nM).3 (–)-Cryptopleurine (500 μg/mL) prevents lesion formation in tobacco (N. tabacum) plants infected with tobacco mosaic virus (TMV). It also inhibits protein synthesis by yeast and mammalian ribosomes.

HY-147826

EGFR-IN-60	EGFR Apoptosis	Cancer
EGFR-IN-60 (Compound 7d) shows obvious inhibition of EGFR ^WT, EGFR ^T790M, EGFR ^L858R and JAK3 with IC₅₀s of 83, 26, 53, and 69 nM, respectively. EGFR-IN-60 potently inhibits the growth of H1975 cells harboring EGFR ^T790M mutation (IC₅₀=1.32 µM) over A431 cells overexpressing EGFR ^WT (IC₅₀=4.96 µM). EGFR-IN-60 exhibits good oral absorption, potent and safe antitumor activity. EGFR-IN-60 induces cell death through apoptosis supported by increased Bax/Bcl-2 ratio .

HY-135727

PF-6422899	EGFR	Cancer
PF-6422899 is an inhibitor for EGFR, that it selectively binds to EGFR and SOAT1 in nanomolar levels .

HY-N15194A

Inostamycin A sodium	Antibiotic	Cancer
Inostamycin A sodium is an antibiotic, which can be found in Streptomyces sp. MH816-AF15. Inostamycin A sodium blocks the phosphatidylinositol turnover, exhibits antimicrobial and cytotoxic activities through inhibition of CDP-DG:inositol transferase. Inostamycin A sodium is promising for research of cancers .

HY-42933

PDGFR-IN-2	PDGFR	Cardiovascular Disease
PDGFR-IN-2 (Compound 16C) is a 4-phenoxyquinoline derivative. PDGFR-IN-2 is a platelet-derived growth factor receptor (PDGFr) inhibitor (IC₅₀: 0.20 μM). PDGFR-IN-2 inhibits the activity of PDGFr tyrosine kinase .

HY-128481

SB24011	STING	Cancer
SB24011 is a STING-TRIM29 interaction inhibitor with a IC₅₀ value of 3.85 μM. SB24011 enhances STING immunity by upregating STING protein levels, thereby enhancing the immunotherapy effect of STING agonists and anti-PD-1 antibodies through systemic anticancer immunity .

HY-143729

EGFR-IN-29	EGFR	Inflammation/Immunology Cancer
EGFR-IN-29 is a potent EGFR inhibitor, example J-022, extracted from Patent WO2021160087 .

HY-149846

SIQ17	EGFR	Cancer
SIQ17 is an EGFR inhibitor that inhibits its activity by occupying the ATP-binding site, with IC₅₀ of 0.62 nM. SIQ17 shows more effective EGFR-TK inhibitory activity compared to the known inhibitor Erlotinib (HY-50896) (IC₅₀ of ∼20 nM). SIQ17 can be used for cancer research

HY-144044

EGFR-IN-30	EGFR	Cancer
EGFR-IN-30 is a potent EGFR inhibitor with IC₅₀s of 1-10 nM, <1 nM for EGFR (WT), EGFR (L858R/T790M/C797S), respectively. EGFR-IN-30 has potential for cell proliferative diseases, such as cancer research .

HY-138556

GPX4-IN-2	Glutathione Peroxidase	Cancer
GPX4-IN-2 is a potent GPX4 inhibitor. GPX4 shows antiproliferative activity. GPX4-IN-2 has the potential for the research of cancer .

HY-144053

EGFR-IN-36	EGFR	Cancer
EGFR-IN-36 is a potent EGFR inhibitor with IC₅₀s of 19.09 nM, 120.01 nM, 2.35 nM for EGFR (WT), HER2 (WT), HER2 (A775_G776insYVMA), respectively. EGFR-IN-36 has potential for wild and/or mutant EGFR and/or HER2 kinase mediated tumors research .

HY-168968S

ZJY-54	EGFR Histone Demethylase	Cancer
ZJY-54 is an orally active dual-target inhibitor of EGFR/LSD1, with IC₅₀ values of 3.8 nM and 0.6 μM, respectively. ZJY-54 can inhibit the proliferation of non-small cell lung cancer cells, induce the accumulation of H3K4me2 and H3K9me2, and inhibit the phosphorylation of the EGFR signaling pathway. ZJY-54 has anti-tumor activity .

HY-146132

EGFR-IN-55	EGFR	Cancer
EGFR-IN-55 (Compound 8a) is a potent EGFR inhibitor with IC₅₀ values of 70 nM and 3.9 nM against EGFR ^WT and EGFR ^L858R/T790M, respectively. EGFR-IN-55 arrests NCI-H1975 cells in G0/G1 phase and shows anticancer activity .

HY-101820

Simotinib	EGFR	Cancer
Simotinib is a selective, specific, and orally bioavailable EGFR tyrosine kinase inhibitor, with an IC₅₀ of 19.9 nM. Antineoplastic activities .

HY-101820R

Simotinib (Standard)	Reference Standards EGFR	Cancer
Simotinib (Standard) is the analytical standard of Simotinib. This product is intended for research and analytical applications. Simotinib is a selective, specific, and orally bioavailable EGFR tyrosine kinase inhibitor, with an IC50 of 19.9 nM. Antineoplastic activities .

HY-119944

JND3229 1 Publications Verification	EGFR	Cancer
JND3229 is a reversible EGFR ^C797S inhibitor with IC₅₀ values of 5.8, 6.8 and 30.5 nM for EGFR ^{L858R/T790M/C797S}, EGFR ^WT and EGFR ^L858R/T790M, respectively. JND3229 has good anti-proliferative activity and can effectively inhibit tumour growth in vivo. JND3229 can be used in cancer research, especially in non-small cell carcinoma .

HY-169982

EGFR-IN-136	EGFR	Cancer
EGFR-IN-136 (compound 21v) is a potent EGFR inhibitor with IC₅₀ values of 20.2, 1.2, 2.3, 12.5 nM for EGFR ^WT, EGFR ^LR/TM, EGFR ^19D/TM/CS, EGFR ^LR/TM/CS, respectively. EGFR-IN-136 shows antiproliferative activity. EGFR-IN-136 shows antitumor activity and has the potential for the research of NSCLC .

HY-P99155A

Zalutumumab (powder)	EGFR	Cancer
Zalutumumab (powder) is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab (powder) binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab (powder) binds with IgG and its Fab fragment with EC₅₀s of 7 and 19 nM, respectively. Zalutumumab (powder) can be used for the research of cancer .

HY-117152

L-threo-Sphingosine L-threo-Sphingosine C-18	p38 MAPK Apoptosis	Cancer
L-threo-Sphingosine is a potent MAPK inhibitor. L-threo-Sphingosine induces apoptosis and clear DNA fragmentation. L-threo-Sphingosine shows anticancer effect .

HY-135815

Mobocertinib 5+ Cited Publications TAK-788; AP32788	EGFR	Cancer
Mobocertinib (TAK-788) is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib can be used in NSCLC research .

HY-13016R

Cabozantinib (Standard)	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib (Standard) is the analytical standard of Cabozantinib. This product is intended for research and analytical applications. Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC₅₀ values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC₅₀=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis .

HY-146210

EGFR-IN-50	EGFR	Cancer
EGFR-IN-50 (Compound 9h) is a potent EGFR inhibitor against L858R resistance mutation (TEL-EGFR-L858R-BaF3: GI₅₀=8 nM, TEL-EGFR-T790M-L858R-BaF3: GI₅₀=6.03 μM). EGFR-IN-50 shows anti-proliferative activity to cancer cells .

HY-135815B

Mobocertinib mesylate TAK-788 mesylate; AP32788 mesylate	EGFR	Cancer
Mobocertinib (TAK-788) mesylate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib mesylate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib mesylate can be used in NSCLC research .

HY-135815A

Mobocertinib succinate 5+ Cited Publications TAK-788 succinate; AP32788 succinate	EGFR	Cancer
Mobocertinib (TAK-788) succinate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib succinate can be used in NSCLC research .

HY-13016A

Cabozantinib hydrochloride XL184 hydrochloride; BMS-907351 hydrochloride	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib hydrochloride is a potent and orally active inhibitor of VEGFR2 and MET, with IC₅₀ values of 0.035 and 1.3 nM, respectively. Cabozantinib hydrochloride displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC₅₀=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib hydrochloride shows antiangiogenic activity. Cabozantinib hydrochloride disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis .

HY-P99155

Zalutumumab	EGFR	Cancer
Zalutumumab is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab binds with IgG and its Fab fragment with EC₅₀s of 7 and 19 nM, respectively. Zalutumumab can be used for the research of cancer .

HY-157413

YS-67	EGFR	Cancer
YS-67 is a potent inhibitor of EGFR with an IC ₅₀ of 5.2 nM. YS-67 significantly inhibits p-EGFR and p-AKT. YS-67 inhibits the proliferation of A549, PC-9, and A431cells with IC ₅₀s of 4.1, 0.5, and 2.1 μM, respectively .

HY-13016

Cabozantinib 40+ Cited Publications XL184; BMS-907351	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC₅₀ values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC₅₀=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis .

HY-135901

Py-MPB-amino-C3-PBD	ADC Cytotoxin Bacterial	Cancer
Py-MPB-amino-C3-PBD is a cytotoxic agent comprised non-alkylating group. Py-MPB-amino-C3-PBD acts as the payload for ADCs. Antimicrobial activity .

HY-18723

Yoda 1 45+ Cited Publications	Piezo Channel Akt ERK Potassium Channel	Cardiovascular Disease
Yoda 1 is a potent and selective Piezo1 agonist. Yoda 1 activates purified Piezo1 channels. Yoda 1 potently inhibits macropinocytosis induced by epidermal growth factor (EGF). Yoda 1 enhances Ca ²⁺ influx followed by activation of the calcium-activated potassium channel KCa3.1 and inhibition of Rac1 activation .

HY-150610

EGFR-IN-69	EGFR	Cancer
EGFR-IN-69 (compound 17g) is a potent EGFR inhibitor, with IC₅₀ values of 4.3, 6.6 and 25.6 nM against EGFR ^{L858R/T790M/C797S}, EGFR ^L858R/T790M, and EGFR ^{19del/T790M/C797S}, respectively. EGFR-IN-69 can be used for non-small-cell-lung-cancer (NSCLC) research .

HY-122241

MT477	PKC	Cancer
MT477 is a potent protein kinase C (PKC) inhibitor. MT477 induces apoptosis and necrosis. MT477 decreases the protein expression of Ras-GTP, p-Erk1/2, p-Elk1. MT477 shows antitumor activity .

Cat. No.	Product Name	Target	Research Area

HY-P10408

Candidalysin	EGFR MMP Calcium Channel NOD-like Receptor (NLR) ERK p38 MAPK	Infection Inflammation/Immunology
Candidalysin is a cytolytic peptide toxin secreted by the fungus Candida albicans. Candidalysin drives epithelial immune responses by activating the EGFR-MAPK signaling pathway, inducing MMP expression and calcium influx, and regulating the c-Fos transcription factor and MKP1 via p38 MAPK and ERK1/2 respectively. Candidalysin is essential for mucosal and systemic infections, activating NLRP3 to promote inflammatory responses, neutrophil recruitment, and Th17 immunity. Candidalysin activates LDH causing membrane damage and exhibiting cytotoxicity

HY-105023

Cyclosporin G	Peptides	Inflammation/Immunology
Cyclosporin G is an active metabolite that can be produced from Tolypocladium inflatum. Cyclosporin G has immunosuppressive activity. Cyclosporin G inhibits proliferation of A431 cells .

Cat. No.	Product Name	Target	Research Area

HY-P99155

Zalutumumab	EGFR	Cancer
Zalutumumab is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab binds with IgG and its Fab fragment with EC₅₀s of 7 and 19 nM, respectively. Zalutumumab can be used for the research of cancer .

HY-P99849

Depatuxizumab ABT-806	EGFR	Cancer
Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer .